New opportunities for cholesterol lowering: focus on PCSK9 inhibitors

Br J Cardiol 2014;21:91–3doi:10.5837/bjc.2014.021 Leave a comment
Click any image to enlarge
First published online July 24th, 2014

Lowering serum cholesterol with statins has consistently shown benefits on cardiovascular outcomes. A 1 mmol/L reduction in low-density lipoprotein (LDL)-cholesterol is associated with approximately one-third fewer coronary events and one-fifth fewer ischaemic strokes.1 However, despite these impressive results, there remains a substantial residual risk of cardiovascular (CV) events despite optimal statin therapy.2 From pooled analyses of randomised-controlled trials of statins, there is a clear relationship between the achieved level of LDL-cholesterol and the number of coronary heart disease (CHD) events. This observation applies to both primary and secondary prevention trials.3 

Pay to access this premium content £5

The BJC is introducing a small charge for some of its premium content. On purchase you will receive an email to access the article and have a downloadable PDF to keep. The PDF can be downloaded from a button on the sidebar. Please note the purchase of this article is for your personal use only.
By supporting us in this way, you are helping us to deliver high-quality services to healthcare professionals. We will continue to keep the majority of our content free of charge.

You can access this article without logging in.
But don't miss out on the many Benefits of our Membership. Register Now.
Already a member? Login Now.